Researchers from St. Vincent’s Institute of Medical Research in Melbourne, Australia, in collaboration with researchers at McMaster University in Canada, are reportedly the first to discover how the type 2 diabetes drug metformin actually works, providing a molecular understanding that could lead to the development of more effective therapies. Mass spectrometry technologies from AB SCIEX, a global leader in analytical technologies, played a critical role in the analysis that led to this breakthrough finding. The research is published in this month’s issue of the journal Nature Medicine.
23 November, 2013
Yet another major contribution from the Stockholm-Uppsala region to accelerating personalized medicine
22 November, 2013
Probe Scientific Ltd, an emerging UK medical device developer, today announced that it had signed a development agreement with BVT Technologies of Brno
20 November, 2013
Lab Innovations - the UK’s only show dedicated to the latest laboratory technology & consumables, analytical & biotech equipment – which took place last week at the NEC, Birmingham, was a huge success.
19 November, 2013
Two technologies which assess the impact of chemicals and pollutants on the lungs and skin without the need for animal testing are joint winners of the 2013 Lush Science Prize.
16 November, 2013
Drug development company Redx Pharma has today reached a landmark agreement with the Royal Liverpool and Broadgreen University Hospitals Trust to work together on new drugs to combat the growing threat of anti-biotic resistance.
06 November, 2013
The Cancer Research Technology Pioneer Fund (CPF) has announced a collaboration with Chroma Therapeutics Ltd to develop cancer drugs targeting macrophages – white blood cells – associated with tumours.This investment by the CPF will accelerate the development of a promising ‘lead’ molecule – taking it from the laboratory into clinical trials for patients.
01 November, 2013